Nonalcoholic Fatty Liver Disease, Cardiovascular Risk, and Carotid Inflammation

Angiology

Volumn 66, Issue 7, 2015, Pages 601-603

  Al Rasadi, Khalid ^a   Rizzo, Manfredi ^b   Montalto, Giuseppe ^b   Berg, Gabriela ^c  

^a SULTAN QABOOS UNIVERSITY HOSPITAL   (Oman)

^b UNIVERSITY OF PALERMO   (Italy)

^c UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; FATTY ACID; FLUORODEOXYGLUCOSE F 18; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LIPOPROTEIN; LIVER TRIACYLGLYCEROL LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MATRIX METALLOPROTEINASE; VERY LOW DENSITY LIPOPROTEIN; BIOLOGICAL MARKER;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY; CAROTID ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; DISEASE ASSOCIATION; DRUG EFFICACY; DYSLIPIDEMIA; ECHOGRAPHY; EDITORIAL; FATTY ACID BLOOD LEVEL; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; MORBIDITY; MORTALITY; NONALCOHOLIC FATTY LIVER; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; RISK FACTOR; SCREENING TEST; BLOOD; CARDIOVASCULAR DISEASES; CAROTID ARTERY DISEASES; COMPLICATION; DISEASE COURSE; FATTY LIVER; PREVALENCE;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CAROTID ARTERY DISEASES; DISEASE PROGRESSION; FATTY LIVER; HUMANS; INFLAMMATION; OXIDATIVE STRESS; PREVALENCE; RISK FACTORS;

EID: 84937869519     PISSN: 00033197     EISSN: 19401574     Source Type: Journal    
DOI: 10.1177/0003319714557353     Document Type: Editorial

References (30)

1. Farrell GC, Larter CZ,. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006; 43 (2 suppl 1): s99-s112.
2. Angulo P,. GI epidemiology: nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2007; 25 (8): 883-889.
3. Musso G, Gambino R, Bo S,. Should nonalcoholic fatty liver disease be included in the definition of metabolic syndrome? A cross-sectional comparison with adult treatment panel III criteria in nonobese nondiabetic. Diabetes Care. 2008; 31 (3): 562-568.
4. Ahmed MH, Barakat S, Almobarak AO,. Nonalcoholic fatty liver disease and cardiovascular disease: has the time come for cardiologists to be hepatologists? J Obes. 2012; 2012: 483135. doi:10.1155/2012/483135.
5. Monsour HP Jr, Frenette CT, Wyne K,. Fatty liver: a link to cardiovascular disease-its natural history, pathogenesis, and treatment. Methodist Debakey Cardiovasc J. 2012; 8 (3): 21-25.
6. Brea A, Mosquera D, Martín E, Arizti A, Cordero JL, Ros E,. Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case-control study. Arterioscler Thromb Vasc Biol. 2005; 25 (5): 1045-1050.
7. Targher G, Bertolini L, Poli F,. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes. 2005; 54 (12): 3541-3546.
8. Nikolic D, Katsiki N, Montalto G, Isenovic ER, Mikhailidis DP, Rizzo M,. Lipoprotein subfractions in metabolic syndrome and obesity: clinical significance and therapeutic approaches. Nutrients. 2013; 5 (3): 928-948.
9. Lucero D, Zago V, López GI,. Does non-alcoholic fatty liver impair alterations of plasma lipoproteins and associated factors in metabolic syndrome? Clin Chim Acta. 2011; 412 (7-8): 587-592.
10. Lucero D, Zago V, López GH,. Predominance of large VLDL particles in metabolic syndrome, detected by size exclusion liquid chromatography. Clin Biochem. 2012; 45 (4-5): 293-297.
11. Zago V, Gorzalczany S, Lucero D, Taira C, Schreier L,. Role of HDL in neutralizing the VLDL effect on endothelial dysfunction. Microvasc Res. 2013; 89: 153-158.
12. Rizzo M, Taylor JM, Barbagallo CM, Berneis KK, Blanche PJ, Krauss RM,. Effects on lipoprotein subclasses of combined expression of human hepatic lipase and human apoB in transgenic rabbits. Arterioscler Thromb Vasc Biol. 2004; 24 (1): 141-146.
13. Miksztowicz V, Lucero D, Zago V,. Hepatic lipase activity is increased in non-alcoholic fatty liver disease beyond insulin resistance. Diabetes Metab Res Rev. 2012; 28 (6): 535-541.
14. Rizzo M, Rini GB, Berneis K,. The clinical relevance of LDL size and subclasses modulation in patients with type-2 diabetes. Exp Clin Endocrinol Diabetes. 2007; 115 (8): 477-482.
15. Rizzo M, Mikhailidis DP,. There is more to predicting vascular disease than just established risk factors. Curr Pharm Des. 2011; 17 (33): 3608-3610.
16. Rizzo M, Pernice V, Frasheri A, Berneis K,. Atherogenic lipoprotein phenotype and LDL size and subclasses in patients with peripheral arterial disease. Atherosclerosis. 2008; 197 (1): 237-241.
17. Mikhailidis DP, Elisaf MS, Rizzo M,. European Panel on Low Density Lipoprotein (LDL) Subclasses: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr Vasc Pharmacol. 2011; 9 (5): 533-571.
18. Cortez-Pinto H, de Moura MC, Day CP,. Non-alcoholic steatohepatitis: from cell biology to clinical practice. J Hepatol. 2006; 44 (1): 197-208.
19. Lucero D, Zago V, López GI,. Pro-inflammatory and atherogenic circulating factors in non-alcoholic fatty liver disease associated to metabolic syndrome. Clin Chim Acta. 2011; 412 (1-2): 143-147.
20. Ross R,. Atherosclerosis is an inflammatory disease. Am Heart J. 1999; 138 (5 Pt 2): S419-S420.
21. Corrado E, Rizzo M, Coppola G, Muratori I, Carella M, Novo S,. Endothelial dysfunction and carotid lesions are strong predictors of clinical events in patients with early stages of atherosclerosis: a 24-month follow-up study. Coron Artery Dis. 2008; 19 (3): 139-144.
22. Sookoian S, Pirola CJ,. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. J Hepatol. 2008; 49 (4): 600-607.
23. Peters SA, den Ruijter HM, Bots ML,. Attenuation of rate of change in carotid intima-media thickness by lipid-modifying drugs: impact on clinical outcomes. Am J Cardiovasc Drugs. 2011; 11 (4): 253-263.
24. Athyros VG, Tziomalos K, Gossios TD, GREACE Study Collaborative Group. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet. 2010; 376 (9756): 1916-1922.
25. Tikkanen MJ, Fayyad R, Faergeman O, IDEAL Investigators. Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels. Int J Cardiol. 2013; 168 (4): 3846-3852.
26. Liao H, Li Z, Zheng D,. Increased Hs-CRP/adiponectin ratio is associated with increase carotid intima-media thickness. Lipids Health Dis. 2014; 13: 120.
27. Miksztowicz V, Fernandez Machulsky N,. Adiponectin predicts MMP-2 activity independently of obesity. Eur J Clin Invest. 2014; 44 (10): 951-957.
28. Berg G, Miksztowicz V, Schreier L,. Metalloproteinases in metabolic syndrome. Clin Chim Acta. 2011; 412 (19-20): 1731-1739.
29. Tan C, Liu Y, Li W,. Associations of matrix metalloproteinase-9 and monocyte chemoattractant protein-1 concentrations with carotid atherosclerosis, based on measurements of plaque and intima-media thickness. Atherosclerosis. 2014; 232 (1): 199-203.
30. Moon SH, Noh TS, Cho YS,. Association between nonalcoholic fatty liver disease and carotid artery inflammation evaluated by 18F-fluorodeoxyglucose positron emission tomography. Angiology. 2015; 66 (5): 472-480.